September 12, 2022
The combination use of cabozantinib plus nivolumab and ipilimumab reduced the risk for disease progression by 27% in patients with previously untreated advanced renal cell carcinoma.
Treatment with radiotherapy and 2 years of ADT may improve outcomes for men following radical prostatectomy, helping patients and physicians make an evidence-based choice.
September 11, 2022
The findings also showed, however, that the further addition of abiraterone acetate and prednisone to the apalutamide/ADT regimen did not significantly boost clinical outcomes.
“Updated results [from the] second interim analysis were consistent with the results from [the first analysis] and showed a continuing trend toward an OS benefit in the ITT population," said Fred Saad, MD, FRCS.
“These data clearly show that the efficacy benefit observed at the primary analysis was robust and maintained with longer follow-up, once again supporting lenvatinib and pembrolizumab as a standard of care in first-line advanced RCC,” said Camillo G. Porta, MD.
The exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.
Although the phase 3 CheckMate 914 trial missed its primary end point of improved DFS, the rate of treatment discontinuation may have played a role in the results, according to Robert J. Motzer, MD.
September 10, 2022
Daniel P. Petrylak, MD, discusses results of a post-hoc analysis of the phase 3 ARCHES trial examining outcomes with enzalutamide/ADT treatment intensification in patients with mHSPC and prior ADT based on patients’ baseline PSA level.
The double-blind phase 3 IMmotion010 trial randomized patients with resected renal cell carcinoma at increased risk of recurrence to adjuvant atezolizumab or placebo.
“Further analysis of patient subsets with this unique trial should help inform future research,” said lead investigator Mohamad Allaf, MD.
